December 2, 2021
Daiichi Sankyo said on November 30 that a multinational PIII clinical study has been initiated for the antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) as a neoadjuvant therapy for high-risk HER2 positive early-stage breast cancer. The PIII study, called DESTINY-Breast11,...read more